Identification of Isoform-Selective Ligands for the Middle Domain of Heat Shock Protein 90 (Hsp90)

The molecular chaperone heat shock protein 90 (Hsp90) is a current inhibition target for the treatment of diseases, including cancer. In humans, there are two major cytosolic isoforms of Hsp90 (Hsp90α and Hsp90β). Hsp90α is inducible and Hsp90β is constitutively e...

Full description

Bibliographic Details
Main Authors: Oi Wei Mak, Raina Chand, Jóhannes Reynisson, Ivanhoe K. H. Leung
Format: Article
Language:English
Published: MDPI AG 2019-10-01
Series:International Journal of Molecular Sciences
Subjects:
Online Access:https://www.mdpi.com/1422-0067/20/21/5333
id doaj-7413e7a45feb4b24875d161364c7bd39
record_format Article
spelling doaj-7413e7a45feb4b24875d161364c7bd392020-11-25T02:50:05ZengMDPI AGInternational Journal of Molecular Sciences1422-00672019-10-012021533310.3390/ijms20215333ijms20215333Identification of Isoform-Selective Ligands for the Middle Domain of Heat Shock Protein 90 (Hsp90)Oi Wei Mak0Raina Chand1Jóhannes Reynisson2Ivanhoe K. H. Leung3School of Chemical Sciences, The University of Auckland, Private Bag 92019, Victoria Street West, Auckland 1142, New ZealandSchool of Chemical Sciences, The University of Auckland, Private Bag 92019, Victoria Street West, Auckland 1142, New ZealandSchool of Chemical Sciences, The University of Auckland, Private Bag 92019, Victoria Street West, Auckland 1142, New ZealandSchool of Chemical Sciences, The University of Auckland, Private Bag 92019, Victoria Street West, Auckland 1142, New ZealandThe molecular chaperone heat shock protein 90 (Hsp90) is a current inhibition target for the treatment of diseases, including cancer. In humans, there are two major cytosolic isoforms of Hsp90 (Hsp90α and Hsp90β). Hsp90α is inducible and Hsp90β is constitutively expressed. Most Hsp90 inhibitors are pan-inhibitors that target both cytosolic isoforms of Hsp90. The development of isoform-selective inhibitors of Hsp90 may enable better clinical outcomes. Herein, by using virtual screening and binding studies, we report our work in the identification and characterisation of novel isoform-selective ligands for the middle domain of Hsp90β. Our results pave the way for further development of isoform-selective Hsp90 inhibitors.https://www.mdpi.com/1422-0067/20/21/5333hsp90virtual screeningintrinsic tryptophan fluorescenceligand bindingisoform-selective
collection DOAJ
language English
format Article
sources DOAJ
author Oi Wei Mak
Raina Chand
Jóhannes Reynisson
Ivanhoe K. H. Leung
spellingShingle Oi Wei Mak
Raina Chand
Jóhannes Reynisson
Ivanhoe K. H. Leung
Identification of Isoform-Selective Ligands for the Middle Domain of Heat Shock Protein 90 (Hsp90)
International Journal of Molecular Sciences
hsp90
virtual screening
intrinsic tryptophan fluorescence
ligand binding
isoform-selective
author_facet Oi Wei Mak
Raina Chand
Jóhannes Reynisson
Ivanhoe K. H. Leung
author_sort Oi Wei Mak
title Identification of Isoform-Selective Ligands for the Middle Domain of Heat Shock Protein 90 (Hsp90)
title_short Identification of Isoform-Selective Ligands for the Middle Domain of Heat Shock Protein 90 (Hsp90)
title_full Identification of Isoform-Selective Ligands for the Middle Domain of Heat Shock Protein 90 (Hsp90)
title_fullStr Identification of Isoform-Selective Ligands for the Middle Domain of Heat Shock Protein 90 (Hsp90)
title_full_unstemmed Identification of Isoform-Selective Ligands for the Middle Domain of Heat Shock Protein 90 (Hsp90)
title_sort identification of isoform-selective ligands for the middle domain of heat shock protein 90 (hsp90)
publisher MDPI AG
series International Journal of Molecular Sciences
issn 1422-0067
publishDate 2019-10-01
description The molecular chaperone heat shock protein 90 (Hsp90) is a current inhibition target for the treatment of diseases, including cancer. In humans, there are two major cytosolic isoforms of Hsp90 (Hsp90α and Hsp90β). Hsp90α is inducible and Hsp90β is constitutively expressed. Most Hsp90 inhibitors are pan-inhibitors that target both cytosolic isoforms of Hsp90. The development of isoform-selective inhibitors of Hsp90 may enable better clinical outcomes. Herein, by using virtual screening and binding studies, we report our work in the identification and characterisation of novel isoform-selective ligands for the middle domain of Hsp90β. Our results pave the way for further development of isoform-selective Hsp90 inhibitors.
topic hsp90
virtual screening
intrinsic tryptophan fluorescence
ligand binding
isoform-selective
url https://www.mdpi.com/1422-0067/20/21/5333
work_keys_str_mv AT oiweimak identificationofisoformselectiveligandsforthemiddledomainofheatshockprotein90hsp90
AT rainachand identificationofisoformselectiveligandsforthemiddledomainofheatshockprotein90hsp90
AT johannesreynisson identificationofisoformselectiveligandsforthemiddledomainofheatshockprotein90hsp90
AT ivanhoekhleung identificationofisoformselectiveligandsforthemiddledomainofheatshockprotein90hsp90
_version_ 1724740332944359424